Neovasc plans to use its newly raised $22.5 million to further fund development efforts for its Neovasc Reducer refractory angina implant and Tiara transcatheter mitral valve.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1fnz5mP
Cap comentari:
Publica un comentari a l'entrada